| Literature DB >> 30083204 |
Zhila Imani1, Zahra Imani2, Leila Basir3, Mohsen Shayeste3, Effat Abbasi Montazeri4, Vahid Rakhshan1.
Abstract
INTRODUCTION: During pulpectomy of primary teeth, cytotoxic medicaments such as formocresol or camphor mono-chlorophenol (CMCP) are used as medicaments. For the first time it is theorized that chitosan can substitute these traditional materials used in pulpectomy of infectious primary teeth. METHODS AND MATERIALS: This preliminary in vitro study consisted of two separate phases (n=75), each of which assessed the antibacterial effects of chitosan versus formocresol and CMCP and positive/negative controls (n=15) on three bacteria types [Enterococcusfaecalis, Staphylococcus aureus, Streptococcusmutans, (n=5 per subgroup)]. Phases 1 and 2 concerned respectively with 1- and 7-day effects of these materials. Bacteria were cultured and injected into sterilized canals and colonies were counted. Medicaments were applied and colonies were re-counted after 1 day of treatment (phase 1). Specimens were re-sterilized and re-randomized, and used for phase 2, in which the same procedures were performed for a 7-day period. Effects of agents on bacteria were analyzed statistically (Kruskal-Wallis α=0.05 and Mann-Whitney α=0.017).Entities:
Keywords: Antibacterial Agents; Camphor Mono-Chlorophenol; Chitosan; CMCP; Enterococcus faecalis; Formocresol; Medicament; Pulpectomy; Staphylococcus aureus; Streptococcus mutans
Year: 2018 PMID: 30083204 PMCID: PMC6064027 DOI: 10.22037/iej.v13i3.20791
Source DB: PubMed Journal: Iran Endod J ISSN: 1735-7497
Descriptive statistics for pre- and post-treatment colony counts, delta colony counts, and percent of colony counts (%RCC) in each subgroup of phase 1, and the results of the Kruskal-Wallis test
|
|
|
|
|
| ||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
|
|
| 11×10 6 (10×10 6) | 484×10 5 (610×10 5) | 232×10 5 (250×10 5) | 388×10 5 (190×10 5) | 0.116 |
|
| 306×10 3 (100×10 3) | 0 (0) | 0 (0) | 436×10 5 (230×10 5) | 0.007 | |
|
| 10694×10 3 (9900×10 3) | 484×10 5 (610×10 5) | 232×10 5 (250×10 5) | -48×10 5 (-40×10 5) | 0.093 | |
|
| 98 (99) | 100 (100) | 100 (100) | -19 (-16) | 0.011 | |
|
|
| 194×10 6 (170×10 6) | 25×10 7 (25×10 7) | 228×10 6 (240×10 6) | 25×10 7 (25×10 7) | 0.300 |
|
| 4926×10 3 (6000×10 3) | 330 (0) | 0 (0) | 257×10 6 (260×10 7) | 0.003 | |
|
| 189074×10 3 (162000×10 3) | 249999670 (25×10 7) | 228×10 6 (240×10 6) | -12×10 6 (-10×10 6) | 0.184 | |
|
| 97 (96) | 100 (100) | 100 (100) | -380 (-5) | 0.003 | |
|
|
| 44400 (42000) | 74360 (10×10 4) | 57360 (65×10 3) | 5×10 4 (5×10 4) | 0.296 |
|
| 40 (0) | 0 (0) | 0 (0) | 52600 (55000) | 0.116 | |
|
| 44360 (42000) | 74360 (10×10 4) | 57360 (65×10 3) | -2600 (-2000) | 0.296 | |
|
| 100 (100) | 100 (100) | 100 (100) | -6 (-4) | 0.117 |
Descriptive statistics for pre- and post-treatment colony counts, delta colony counts, and percent of colony counts (%RCC) in each subgroup of phase 2, and the results of the Kruskal-Wallis test
|
|
|
|
|
| ||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
|
|
| 264×10 6 (200×10 6) | 248×10 5 (210×10 5) | 142×10 5 (100×10 5) | 372×10 5 (200×10 5) | 0.008 |
|
| 31×10 4 (30×10 4) | 0 (0) | 0 (0) | 34×10 6 (19×10 6) | 0.007 | |
|
| 26369×10 4 (19970×10 4) | 248×10 5 (210×10 5) | 142×10 5 (100×10 5) | 32×10 5 (20×10 5) | 0.008 | |
|
| 100 (100) | 100 (100) | 100 (100) | 11 (8) | 0.007 | |
|
|
| 1728×10 5 (1400×10 5) | 1088×10 5 (700×10 5) | 42×10 5 (20×10 5) | 3×10 8 (3×10 8) | 0.007 |
|
| 1196×10 3 (900×10 3) | 0 (0) | 0 (0) | 272×10 6 (270×10 6) | 0.007 | |
|
| 171604×10 3 (139870×10 3) | 1088×10 5 (700×10 5) | 42×10 5 (20×10 5) | 28×10 6 (30×10 6) | 0.327 | |
|
| 99 (100) | 100 (100) | 100 (100) | 9 (10) | 0.000 | |
|
|
| 13×10 4 (3×10 4) | 10×10 4 (10×10 4) | 58×10 3 (65×10 3) | 48×10 3 (50×10 3) | 0.042 |
|
| 0 (0) | 0 (0) | 0 (0) | 44×10 3 (47×10 3) | 1.000 | |
|
| 13×10 4 (3×10 4) | 10×10 4 (10×10 4) | 58×10 3 (65×10 3) | 40×10 2 (30×10 2) | 0.042 | |
|
| 100 (100) | 100 (100) | 100 (100) | 9 (10) | 1.000 |
Figure 1Colony counts in the pre- and post-treatment sessions, in phases 1 (left) and 2 (right
Asymptotic P-values calculated using Mann-Whitney U test between both phases
|
|
|
|
|
| |
|---|---|---|---|---|---|
|
|
| 0.009 | 0.834 | 0.009 | 0.094 |
|
| 0.175 | 1.000 | 0.175 | 1.000 | |
|
| 0.600 | 1.000 | 0.600 | 1.000 | |
|
| 1.000 | 0.347 | 0.009 | 0.009 | |
|
|
| 0.458 | 0.175 | 0.465 | 0.173 |
|
| 0.035 | 0.136 | 0.036 | 0.136 | |
|
| 0.009 | 1.000 | 0.009 | 1.000 | |
|
| 0.228 | 0.674 | 0.009 | 0.009 | |
|
|
| 0.915 | 0.134 | 1.000 | 0.136 |
|
| 0.521 | 1.000 | 0.521 | 1.000 | |
|
| 0.916 | 1.000 | 0.916 | 1.000 | |
|
| 1.000 | 0.602 | 0.009 | 0.008 | |